Abstract

PurposeThe three most widely used utility measures are the Health Utilities Index Mark 2 and 3 (HUI2 and HUI3), the EuroQol-5D (EQ-5D) and the Short-Form-6D (SF-6D). In line with guidelines for economic evaluation from agencies such as the National Institute for Health and Clinical Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH), these measures are currently being used to evaluate the cost-effectiveness of different interventions in MS. However, the challenge of using such measures in people with a specific health condition, such as MS, is that they may not capture all of the domains that are impacted upon by the condition. If important domains are missing from the generic measures, the value derived will be higher than the real impact creating invalid comparisons across interventions and populations. Therefore, the objective of this study is to estimate the extent to which generic utility measures capture important domains that are affected by MS.MethodsThe available study population consisted of men and women who had been registered after 1994 in three participating MS clinics in Greater Montreal, Quebec, Canada. Subjects were first interviewed on an individualized measure of quality of life (QOL) called the Patient Generated Index (PGI). The domains identified with the PGI were then classified and grouped together using the World Health Organization’s International Classification of Functioning, Disability and Health (ICF), and mapped onto the HUI2, HUI3, EQ-5D and SF-6D.ResultsA total of 185 persons with MS were interviewed on the PGI. The sample was relatively young (mean age 43) and predominantly female. Both men and women had mild disability with a median Expanded Disability Status Scale (EDSS) score of 2. The top 10 domains that patients identified to be the most affected by their MS were, work (62%), fatigue (48%), sports (39%), social life (28%), relationships (23%), walking/mobility (22%), cognition (21%), balance (14%), housework (12%) and mood (11%). The SF-6D included the most number of domains (6 domains) important to people with MS, followed by the EQ-5D (4 domains) and the HUI2 (4 domains) and then the HUI3 (3 domains). The mean and standard deviation (SD) for the PGI, EQ-5D and the SF-6D were 0.50 (SD 0.25), 0.69 (0.18) and 0.69 (0.13), respectively. The magnitude of difference between the PGI and the generic utility measures was large and statistically significant.ConclusionAlthough the generic utility measures included certain items that were important to people with MS, there were several that were missing. An important consequence of this mismatch was that values of QOL derived from the PGI were importantly and significantly lower than those estimated using any of the generic utility measures. This could have a substantial impact in evaluating the effect of interventions for people with MS.

Highlights

  • Multiple sclerosis (MS) is a chronic disease resulting from inflammation and demyelination in the central nervous system (CNS) [1] that is associated with a variety of symptoms, such as fatigue, impaired mobility and cognitive decline [2]

  • A total of 185 persons with MS were interviewed on the Patient Generated Index (PGI)

  • An important consequence of this mismatch was that values of quality of life (QOL) derived from the PGI were importantly and significantly lower than those estimated using any of the generic utility measures

Read more

Summary

Introduction

Multiple sclerosis (MS) is a chronic disease resulting from inflammation and demyelination in the central nervous system (CNS) [1] that is associated with a variety of symptoms, such as fatigue, impaired mobility and cognitive decline [2]. Behavioural [3,4,5,6,7,8,9], medical [10,11,12,13,14], and surgical [15,16,17,18,19], have been developed in the field of MS As there are both benefits and harms from interventions, the importance of considering the patient’s perspective in the evaluation of these new therapies is increasingly being emphasized. Patientreported outcomes are used to evaluate the patient’s perspective on the impact of the disease and its treatment on symptoms, function, and other aspects of quality of life (QOL). A term often confused with HRQL, is a description and/or measurement of the health of an individual or population at a particular point in time against identifiable standards [24]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call